Normal ranges of angiogenesis regulatory proteins in human platelets

American Journal of Hematology

Volumn 85, Issue 7, 2010, Pages 487-493

  Peterson, Jon E ^a,b   Zurakowski, David ^b   Italiano Jr , Joseph E ^b,c   Michel, Lea V ^a,d   Fox, Lucius ^a   Klement, Giannoula L ^e   Folkman, Judah ^b  

^a Ortho Clinical Diagnostics ^*  (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; VASCULOTROPIN; ANGIOGENIC PROTEIN; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN A;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOGENESIS; ARTICLE; BLOOD CELL COUNT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REFERENCE VALUE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOCYTE VOLUME; CHEMISTRY; MIDDLE AGED; STANDARD;

ADULT; ANGIOGENIC PROTEINS; BLOOD PLATELETS; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PLATELET-DERIVED GROWTH FACTOR; REFERENCE VALUES; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954944628     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21732     Document Type: Article

References (37)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936.
2. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-287.
3. Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 2000;85:40-45.
4. Nguyen M. Angiogenic factors as tumor markers. Invest New Drugs 1997;15:29-37.
5. Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 2003;44:213-222.
6. Molica S, Vacca A, Levato D, et al. Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res 2004;28:321-324.
7. Ribatti D, Scavelli C, Roccaro AM, et al. Hematopoietic cancer and angiogenesis. Stem Cells Dev 2004;13:484-495.
8. Dosquet C, Coudert MC, Lepage E, et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-2458.
9. Abendstein B, Daxenbichler G, Windbichler G, et al. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res 2000;20:569-572.
10. George ML, Eccles SA, Tutton MG, et al. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res 2000;6:3147-3152.
11. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of Tamoxifen. Cancer Res 2000;60:2898-2905.
12. Wynendaele W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo? Ann Oncol 1999;10:965-971.
13. Lee JK, Hong YJ, Han CJ, et al. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen? Int J Oncol 2000;17:149-152.
14. Klement GL, Kikuchi L, Kieran M, et al. Early tumor detection using platelet uptake of angiogenesis regulators. Blood 2004;104:839; ASH Annual Meeting Abstracts.
15. Klement GL, Yip T-T, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood 2009;113:2835-2842.
16. Hartwig JC.The platelet cytoskeleton. In: Gresele P,Fuster V,López JA,Page CP,Vermylen J, editors. Platelets in Hematologic and Cardiovascular Disorders. New York: Cambridge University Press; 2008. pp75-97.
17. Fraser CG.Changes in serial results. In: Biological Variation: From Principles to Practice: Washington, DC: AACC Press; 2001. pp 67-90.
18. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
19. Shing Y, Folkman J, Sullivan R, et al. Heparin affinity: Purification of a tumorderived capillary endothelial cell growth factor. Science 1984;23:1296-1299. (Pubitemid 14163183)
20. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
21. Lawler JW, Slayter HS, Coligan JE. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem 1978;253:8609-8616.
22. Hart CE, Bailey M, Curtis DA, et al. Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. Biochemistry 1990;29:166-172.
23. Suvarna S, Espinasse B, Lubica RQR, et al. Determinants of PF4/heparin immunogenicity. Blood 2007;110:4253-4260.
24. Elzinga M, Collins JH, Kuehl WM, Adelstein RS. Complete amino-acid sequence of actin of rabbit skeletal muscle. PNAS 1973;70:2687-2691.
25. Altman DG. Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall/CRC; 1991. pp419-431.
26. Kut C, Gabhann FM, Popel AS. Where is VEGF in the body? A meta analysis of VEGF distribution in cancer. Br J Cancer 2007;97:978-985.
27. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5:487-491.
28. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004;36:961-968.
29. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J of Haematol 1997;97:441-448.
30. Feldman AL, Alexander HR Jr, Bartlett DL, et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 2001;8:741-745.
31. Brill A, Varone D.Angiogenesis. In: Michelson AD, editor. Platelets. Boston: Elsevier Press; 2007. pp 757-768.
32. Italiano JE Jr.The structure and production of blood platelets. In: Gresele P,Fuster V,López JA,Page CP,Vermylen J, editors. Platelets in Hematologic and Cardiovascular Disorders. New York: Cambridge University Press; 2008. pp 1-20.
33. Italiano JE Jr, Richardson JL, Patel-Hett S. Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate alpha granules and differentially released. Blood 2008;111:1227-1233.
34. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-2190.
35. Blann AD. Angiogenesis and platelets: The clot thickens further. Cardiovasc Res 2004;63:192-193.
36. Trikha M, Nakada MT. Platelets and cancer: Implications for antiangiogenic therapy. Semin Thromb Hemost 2002;28:39-44.
37. Salgado R, Vermeulen PB, Benoy I, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999;80:892-897.